OliX Pharmaceuticals Wins Australian Approval for Phase 2a Trial of OLX10212

Bitget2026/10/30 07:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

OliX Pharmaceuticals received Bellberry HREC approval on Oct. 30, 2026, for a Phase 2a trial of OLX10212.
The trial targets 64 patients with bilateral age-related macular degeneration with geographic atrophy.
The randomized, sham-controlled study will assess efficacy and safety, with completion expected Sept. 30, 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OliX Pharmaceuticals Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261030900713), on October 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

OliX Pharmaceuticals Wins Australian Approval for Phase 2a Trial of OLX10212

You may also like

Crypto prices